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By E. E. POCHIN, M.D, F.R.C.P.*
The Iiobert Campeill Oration, delivered on 26th February, 195?
I AM very much honoured by your invitation that I should deliver an oration in this
valuable and distinguished series that has been established in memory and honour
of the life of Robert Campbell, and I wish to speak of the clinical value of
radioactive isotopes.
In the year in which the Robert Campbell memorial orations were founded,
Rutherford had already detected faint scintillations on the screen of a chamber
in which nitrogen atoms were being bombarded with helium nuclei (Rutherford
and others, 1930). These scintillations were due to the formation of oxygen atoms
from nitrogen, and the first isotope had been artificially produced.
The ensuing thirty years have seen this subject develop in a way, and with a
speed, that would have satisfied Campbell's instinct for the application of new
knowledge and techniques; with the first radioactive isotope being prepared in
measurable quantities in 1934 (Fermi and others, 1934), used in animals and in
man soon after, and by 1942 in the treatment of human disease (Hamilton and
Lawrence, 1942; Hertz and Roberts, 1942). Since then the clinical uses of these
materials have increased rapidly. My title, however, is not the clinical uses, but
the clinical value, of radioactive isotopes, for it has become obvious in the last few
years that certain isotopes had more than a purely experimental interest and, to-day,
their clinical use is essential, in the sense that certain of our patients will be
improperly treated or inadequately investigated, without their help. And so I shall
speak mainly about the methods that are of direct clinical importance. Even so,
I shall need to illustrate rather than to enumerate all the present applications of
radioisotopes in clinical medicine. I will be dealing in particular with radioactive
iodine, which was one of the first to be produced, and to be used in therapy, and
which is one in which my own department has been interested. It is perhaps a
fitting example, also, since it has important applications to the investigation and
surgery of the thyroid gland, which Robert Campbell so much advanced by his
surgical skill and published work.
I would like to start by explaining the meaning of some of the rather unfamiliar
terms that are used in this subject, and those of you who are accustomed to work
with isotopes and their radiations will, I hope, excuse this. So, firstly, what exactly
is an isotope? You will remember, perhaps, that different atoms differ, not only in
the weight of their nuclei, but also in the size of the electrical charges on them.
*Based in part on work undertaken for the Medical Research Council, London, in the Department
of Clinical Research, University College Hospital Medical School, London.
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FNow it is the nuclear charge, and not the nuclear weight, which determines the
chemical properties of the atom. For example, any atom with a charge of 53 units
on the nucleus will have 53 electrons in their orbits round the nucleus, and these
will give it the chemical properties of iodine, whatever the nuclear weight may
happen to be. In fact, we know of atoms of every atomic weight from 124 to 137,
but all having a charge of 53, so that all these different atoms are forms of iodine,
and are known as its isotopes (Table I). Now, only one of these iodines, that with
TABLE I.
PROBABLE ISOTOPES OF IODINE.
Charge. Weight. Half-period of
Radioactive decay.
53 ... 122 ... 4 minutes.
124 ... 4 days.
,, ... 125 ... 60 days.
,, ... 126 ... 13 days.
,, .. . 127 ... STABLE.
,, ... 128 ... 25 minutes.
,, ... 129 ... (long).
,, ... 130 ... 13 hours.
131 ... 8 days.
,, ... 132 ... 2 hours.
,, ... 133 ... 22 hours.
,, ... 134 ... 54 minutes.
,, ... 135 ... 7 hours.
,, ... 136 ... 2 minutes.
,, ... 137 ... 22 seconds.
atomic weight 127, is stable; all the rest are unstable, and undergo radioactive
decay more or less rapidly. It is thus only iodine 127 that normally occurs in
the thyroid or in nature. But the other and radioactive isotopes can be prepared
by physical methods, for example, in the plutonium pile. The most convenient for
clinical purposes is iodine 131, of which half undergoes radioactive decay within
every eight days. In just the same way, radioactive forms of sodium, carbon,
phosphorus, potassium and most other important elements are available, and all of
them are chemically indistinguishable from the corresponding normal elements.
Now the advantages of this are evident. We can give a dose of radioactive iodine
in the knowledge that the body cannot distinguish it chemically from ordinary
iodine; it will go exactly where ordinary iodine is going, it will be metabolised
at the same rate, and will be shared between thyroid and kidney in the same
proportion as for ordinary iodine. Yet, although its chemical metabolism is
identical, its presence can be detected by means of its radioactivity with very
great sensitivity; or, if large quantities are given, its radiations can be utilised
to produce intense local radiation and tissue destruction at the sites where the
18isotope is most highly concentrated. These radioactive iodine atoms form, in fact,
the perfect "fifth column"; we send them out in uniforms which make them
indistinguishable from the enemy, with whom they mix and move freely; and we
equip them with wireless transmitters, so that they can signal their movements,
and therefore his movements, continuously. Or, if we send out large numbers,
they return with the enemy to all his sites of concentration and proceed to blow them
up.
XVe must distinguish between these r6les of intelligence and sabotage, between
our use of the isotope's radioactivity for its detection or for tissue destruction at
the sites where it is selectively concentrated. And with radioiodine this distinction
is clear-cut, since it requires about one thousand times as much of the isotope to
cause effective tissue destruction as it does to allow useful measurement of thyroid
function. (Table II.)
1 ABLE II.
131
TEST DosEs I THERAPY DosEs
1 1
10 100 Millicuries 100 10
(10) (100) (microcuries)
Tests of Maps of Graves's Thyroid
function distribution disease carcinoma
measurement of partial total
radioiodine destruction of a
quantity localisation strongly weakly
wvithin thyroid, I-concentrating
etc. tissue
It will be seen that the diagnostic tests with which we shall be concerned require
only small fractions of a millicurie, whereas radioiodine therapy requires many
millicuries. I should mention that a millicurie of any radioisotope is the amount
in which atomic disintegrations are occurring as frequently as in a millicurie of
radium, that is, in a milligram of radium in equilibrium with its products; so that
in each millicurie of any radioactive isotope, about forty million atomic disintegra-
tions are occurring each second. With the test doses of radioiodine, the irradiation
outside the thyroid is quite negligible, and even within the thyroid it may be no
higher than is received by large areas of the body during two minutes' X-ray
screening after a barium meal or in the chest clinic. To the patient, the radiation
hazard of the smaller test doses at least is as negligible as in many routine radio-
diagnostic procedures. Rather larger test doses are needed to map out the
distribution of iodine within the thyroid gland or in the neck, but they are still
withlout detectable effect on thyroid or any other function. Even at the much
19
Ghigher level of dosage for therapy in Graves's disease, where the thyroid will
receive several thousand rcentgens of irradiation, blood changes are not normally
seen and the menstrual periods are undisturbed; and they are normally uninfluenced
even by the higher doses still that are required for thyroid carcinomata, which do,
however, produce a transient depression of the blood lymphocyte count, lasting for
perhaps a fortnight.
Let us consider in turn the uses of isotopes for simple tests of function, for
mapping the distribution of elements within the body, and for various types of
therapy.
I will illustrate first how a radioactive isotope can be used to give a simple
measure of thyroid function. When radioiodine is taken by mouth, most of what
is lost from the body is excreted in the urine, and most of what is retained is
concentrated in the thyroid. If, therefore, we give a dose of radioiodine having
measured its radioactivity, and collect the urine excreted for the next forty-eight
hours and determine its total radioactivity, we can calculate the proportion
of the ingested radioiodine that has been lost from the body, and therefore the
proportion that has been retained by the thyroid. But since the thyroid cannot
distinguish radioiodine from normal iodine, this is a valid measure of the
iodine avidity of the gland (Skanse, 1949; Fraser and others, 1953). This is a
simple measurement, taking perhaps ten minutes to perform, and the radioactivity
of liquids can be determined with ease and sensitivity, so that small doses can
be used.
But you may say that you do not wish to rely on the complete collection of urine
and that you want to estimate the thyroxine output rather than merely the iodine
uptake of the gland. Suppose, therefore, that a known dose of radioiodine is given,
and forty-eight hours later a plasma sample is taken. If we precipitate the thyroxine
content of this plasma with a protein precipitant, and measure the radioactivity of
this precipitate, we can deduce the amount of our radioiodine which, in the
intervening two days, has been incorporated into thyroxine and discharged into
the plasma. In normal subjects, less than 0.4 per cent. of the dose is protein-bound
by this time as thyroxine per litre of plasma, whereas higher concentrations of up
to 5 per cent. per litre are regularly reached in hyperthyroidism, owing to the
more rapid thyroxine production in this condition (Goodwin and others, 1951). We
may recognise from this test certain merits of the isotope technique: we give our
radioiodine by mouth and identify its arrival in the plasma; we determine its actual
concentration in plasma and, by simple fractionation, its concentration in a
particular chemical form; and, since we know the moment and the only moment
at which this type of iodine was given, we can establish a value for the rate of
synthesis of the radioactive thyroxine and therefore of thyroxine as a whole, since
the two forms of iodine are indistinguishable chemically and metabolically.
It is clear that measurements of this kind have a wide application in clinical
medicine, and many are already being used. Radioactive iron may be given orally
in different chemical forms (Moore and others, 1944) or in different types of
20anawiiia (Dubach and others, 1948), and its efficiency of absorption estimated from
plasma samples; or radioiron given intravenously, to measure its degree and
speed of incorporation into hvemoglobin and the red cell (Finch and others, 1949).
Red cells can be made recognisable by labelling with radioactive phosphorus (Reeve
and Veall, 1949), chromium or iron (Gibson and others, 1946), and injected intra-
venously in known amounits so that the blood volume, the total red cell volume
of the blood, can be deduced from the radioactivity of blood samples withdrawn
after circulatory mixing has occurred. The same principle allows the total
exchangeable sodium or potassium of the body, for example, in Addison's disease,
to be measured, by allowing a known quantity of the appropriate isotope, radio-
sodium or radiopotassium, to mix throughout the body, and then establishing its
concentration in a sample of plasma. The procedure is indeed widely applicable
to measuring the absorption of any suitable element, for example, through the
wall of the gut, the skin or the capillaries, and into the plasma, the urine, the
C.S.F. or the amniotic fluid; and many such uses have been developed (Low-Beer,
1950). It can be extended to cover the absorption or movement of chemical
compounds or biological structures, if these can be labelled by the attachment of a
radioactive element which remains stably attached during the course of the
observation. Moreover, the scope of such methods can clearly be usefully extended
if the circumstances or value of the test call for examination by biopsy. In fracture
of the neck of the femur, the vascularity of the femoral head can be established
by administration of radiophosphorus several hours before operation. If, at
operation, the isotope is found to be well concentrated in bone from the head of
the femur, it indicates that there must be an adequate circulation to the femoral
head, but if not, the head is likely to have inadequate circulation and avascular
necrosis will probably occur later (Tucker, 1950).
By an obvious extension of this method, radiophosphorus is proving of value
during operations for cerebral tumour. Probably because of their higher cellularity
and vascularity, many such tumours are found to develop higher concentrations of
phosphorus, and therefore of radiophosphorus, than normal cerebral tissue. If a
patient has receivedl radiophosphorus before operation, the higher radioactivity of
tumour than normal tissue can be recognised if a probe incorporating a counter
is passed into it (Selverstone and others, 1949). Morley and Jefferson (1952) have
recently described the practical value of this in determining the extent of tumour
infiltration at operation.
All the methods we have discussed so far depend on measuring the radiations of
material which can be placed in contact with a suitable counter tube, whether the
material is a liquid sample of plasma or urine, or the cerebral tumour tissue into
Nwhich a counter is introduced. Most radioisotopes, however, also emit a form of
radiation, gamma radiation, which will penetrate several inches of tissue with little
re(duction in intensity. This immediately throws open a further range of investiga-
tions, which are often of considerable clinical value and importance. If a test
dose of radioiodine is given intravenously or by mouth its arrival in the thyroid
21can not only be detected, but can be measured and followed quantitatively by a
Geiger counter placed in front of the neck opposite the gland. Moreover, if this
counter is suitably shielded with lead, it will measure radiations from radioiodine
in the thyroid, but those from radioiodine in other positions will be stopped by the
lead. The Geiger counter itself consists simply of a glass tube containing two
wires with a potential difference between them, but insulated from each other so
that normally no current flows. When, however, a radiation from a disintegrating
atom passes through the tube, it momentarily ionises the gas in the tube and a
brief current flows. The frequency with which such currents flow thus correspolds
with the number of atoms disintegrating, which in turn is proportional to the
amount of the radioactive isotope present. So the counting rate varies simply
with the amount of radioiodine in the thyroid and, with suitable calibration (Myant
and others, 1949), can be expressed as a given percentage of the dose in the gland
at the time.
May I illustrate this method by a test we use in the diagnosis of hyperthyroidism
(Pochin, 1950)? l'he patient drinks a small dose of a radioiodine solution. Two
hours later she returns and measurements are made with a counter opposite the
neck, and opposite some other body area such as the thigh. Now, clearly, the
more active the thyroid, the more radioiodine will have been taken up by the
thyroid in these two hours, and the less will be left in the rest of the body, as
indicated by the thigh. A simple ratio of the neck to the thigh counting rate
seems in fact to give as useful diagnostic information as the basal metabolic rate,
being greatlIy raised above normal in most hyperthyroid patients. The test involves
about five minutes' measurements in the out-patient clinic. Even the (lose need
not be calibrated exactly, since the result depends simply on a ratio of two counting
rates measuring the proportion of the close that is in the thyroid to that which
is left in the rest of the body two hours after administration. And the radiation
received by the thyroid is comparable to that received by the whole abdomen during
the barium meal examination.
Many other applications of external counting have been or are being developed-
timing the rate of venous flow by injecting radiosodium at the ankle ancd recording
its arrival at the groin (Payling WVright and others, 1948); timing the absorption
of drugs fronm an injection site (Reiner and others, 1943); studying the lymphatic
removal of colloid or protein ml-aterial; and measurement of circulation time from
one ventricle of the heart to the other (Prinzmetal and others, 1949). Or if radio-
sodium is injected into a pedicle skin flat (Barron and others, 1951) and is found
to be rapidly removed through one end of the pedicle, an efficient circulation
must have been established through this end; and by detecting the vascularisation
of flaps in this way the transfer and establishment of such grafts can be safely
accelerated, and the patient's stay in hospital and in plaster is often more than
halved by using this test.
It is an obvious extension of these measurements of the total amount of radio-
isotope in a given region to map out in more detail how it is distributed within
the region. This requires rather higher doses of radioisotope and shielding of the
22counter so that the amount of isotope under the skin at each point can be measured
without interference from that in adjacent areas. With suitable equipment and
quite moderate dosage, it is easy to map the outlines of a retrosternal goitre
(Fig. 1), the process involving perhaps twenty minutes' work, a few days after
administration of a test dose. It may also be useful to determine in this way the
size of the thyroid, the activity of different parts of the gland, and even sometimes
its position in the neck in those hyperthyroid patients requiring thyroidectomy, but
in whom the gland is not palpable (Fig. 2).
Fig. I
Map of areas of radioiodine concentration (contours of equal activity
shown by interrupted lines) in the neck, indicating retrosternal
extension of the thyroid gland.
Although most techniques of mapping are concerned with radioiodine and thyroid
tissue, several such procedures are of value in the control of other types of radio-
isotope treatment as will be discussed later; and the method is of wide application.
Certain cerebral tumours concentrate diiodofluorescein, of which the iodine, if
radioactive, may be detected by counters external to the skull, although at present
without great accuracy (Belcher and others, 1952). The placental site can be
identified in placenta prwevia if the circulating blood is labelled with radiosodium
(Browne and Veall, 1950), and it is reported that the utilisation of oral iron in
bone marrow or in the body iron stores may be followed by counts over livrer,
spleen and bones after ingestion of radioiron.
It appears, therefore, that the radioisotopes offer a versatile range of methods
for examining many funct;ions of the living body without significant radiation
hazard. Whether these depend upon fluids removed from the body, or on biopsy,
or on external counts over the body, the measurements can be strictly quantitative,
23
Hthev refer to material administered at a known time and they sample the normal
body metabolism without disturbing it, thanks to the sensitivity of the detection
methods and the small doses of isotope that can be given.
When, however, we turn to the therapeutic applications of the radioactive
isotopes the emphasis is entirely different, although the underlying principles are
the same. We are now seeking, as in all radiotherapy, to achieve intense radiation
where it is required, with as little radiation as possible elsewhere in the body.
Now with almost all the isotopes used therapeutically, it is the beta radiation which
Fig. 2
Map of radioiodine concentration in the neck, showing an impalpable
but over-active gland to be in a low normal position.
is responsible for most of the radiotherapeutic effect, and this is due to the emission
of electrons which penetrate at most a few millimetres through tissue, so that the
tissue destruction is largely confined to the actual areas in which the isotope is
concentrated. This gives us two possibilities-either of irradiating a surface by
producing a high concentration of radioactive material over that surface; or of
irradiating a tissue mass by isotopes distributed throughout that mass. In each case
we require to achieve a high local concentration of isotope, with as little of the
isotope as possible circulating in the rest of the body.
The irradiation of surfaces is proving clinically valuable in several ways. Simple
and effective beta radiation applicators to the skin can be obtained using radio-
active phosphorus. Similar possibilities arise with internal surfaces and radioactive
materials are being used within latex bags introduced into the bladder to irradiate
papillary carcinoma of the bladder (Walton and Sinclair, 1952). Nor need the
containing sac be an artificial one, for it is found that colloidal materials introduced
into the peritoneal or pleural cavity only escape slowly through the peritoneum or
pleura. If a colloidal suspension of radiogold is injected intraperitoneally, it
24sediments rapidly (Fig. 3) and fairly uniformly on to the peritoneal surface,
an(i most of it remains there or just below the surface during the whole period
of its effective radioactivity-a little passing to the regional lymph glands but
negligible amounts to the blood or body as a whole. In patients with rapidly
recurring malignant ascites, due to deposits of peritoneal carcinoma, intraperitoneal
radiogold will produce an intense local radiation largely confined to the peritoneal
surface, and may abolish the formation of ascites which is the main initial limitation
on health in some patients. Since the radiation only penetrates a millimetre or
%Concentration/ litre.
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Fig. 3
Concentrations of colloidal radioactive gold in ascitic fluid on
successive days after its injection, indicating rapid precipitation on
to the peritoneum. Values corrected for decay.
so from the peritoneal surface, this treatment can only be palliative where sub-
stantial carcinomatous masses are present. It might, however, be curative where
seedling deposits only were present, as after the operative rupture of a malignant
ovarian cyst. Radiogold has a similar value when given intrapleurally for recurrent
pleural effusion of malignant origin, and we have reduced the frequency of
aspiration in one such case from daily to three-weekly aspiration from each pleural
cavity.
Radioactive gold undergoes radioactive decay rather rapidly, and delivers most
of its radiation in the first few days from the time of its injection. Even when
injected subcutaneously in the region of a tumour, it therefore remains at the site
of injection for long enough to be valuable therapeutically (Hahn, 1951) in much
25the same way as with radium or radon implantations, but often with a better and
more uniform dose distribution within the affected tissues, and such removal as
occurs up the lymphatics from the affected area may in itself be helpful. Attempts
are being made to treat carcinoma of the prostate by local injection through a
cystotomy (Flocks and others, 1902), and bronchial carcinoma by local injection
into the bronchus (Hahn and Carothers, 1951).
Now you will notice that we have so far been discussing therapeutic methods
in which the isotope is placed in apposition with the tumour or affected tissue.
But in some circumstances if we administer a suitable preparation of isotope,
we can leave the body to concentrate it in the right positions, on account either
of the physical or of the chemical properties of the preparation used.
I I~~~~~~t
Fig. 4
Map of colloidal radiogold concentration in the chest after intravenous
injection of a large particle suspension, indicating selective concen-
tration in the lungs. Data in a case of pulmonary adenocarcinomatosis.
Concentration, based on physical properties, has more interest and promise than
immediate value. If a suspension of colloidal material, say radiogold, is injected
into a systemic vein, it will be carried by the circulation through the heart, but
if the particle size is sufficiently large, the particles will be unable to pass through
the lung capillaries and the radioactive substance will remain localised in the
lungs. We have attempted to treat a patient with multiple adeno-carcinomatosis
of the lungs in this way and obtained a high concentration of isotope within the
lungs (Fig. 4) with no detectable escape to other parts of the body, although we
did not achieve a sufficient dose to influence the tumour growth (Pochin, 1951).
Or, if colloidal gold is given intravenously in small particle size, the particles are
26removed by the reticulo-endothelial system and become concentrated mainly in
the liver. Fig. 5 shows the distribution of radiogold achieved in this way in a
patient with a primary hepatoma where again a selective but still inadequate
local concentration was reached in the liver. This technique has been used with
colloidal preparations of various radioisotopes using the oxide of radioactive
manganese and chromic radiophosphate as well as radiogold, in chronic leukemias
and Hodgkin's disease, but without outstanding success.
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Fig. 5
Map indicating radiogold concentration in the liver in a case of
primary hepatoma injected with colloidal radiogold of small particle
size. Hatched margin indicates the liver edge to percussion and
palpation.
At present, the most valuable methods depend upon chemical localisation of the
isotope-of radioiodine for hyperthyroidism and certain thyroid carcinomata and
of radiophosphorus for polycythemia.
It is well known that iodine reaches a concentration in the thyroid which is
several hundred times that in the body as a whole. Since this holds equally for
radioiodine, it follows that the thyroid can be given destructive irradiation of
several thousand rcentgens with an amount of radioiodine that is trivial in its
effects on the body as a whole. The thyroid overactivity in Graves's disease can
thus be abolished very simply by a suitable dose of radioiodine-a most attractive
treatment to the patient who is spared the need for operation or for prolonged
supervision during the administration of thiouracil. She simply takes what appears
to be a drink of cold water-for the amount of the iodide in a millicurie is less
than a hundredth of a microgram and quite unnoticeable-and, if she is still
thyrotoxic two months later, another drink.
This apparent simplicity is, perhaps, deceptive, and for three reasons. Firstly,
these isotopes are somewhat hazardous to handle in therapeutic amounts, highly
27specialised equipment is required in the control of dosage, and some care is needed
in dealing with the radioactive urine which is passed for the first days after the
dose. Secondly, our methods of calculating the necessary dose are not yet precise,
largely owing to differing radio-sensitivity of different glands; and a rcentgen
dosage which will fail to abolish the toxicity of one gland may induce myxcedema
in the next. And thirdly, we do not yet know that the risks of carcinogenesis
from this form of treatment are negligible. Radioiodine was first used in the
United States in the treatment of Graves's disease over ten years ago, and several
thousand patients have now been treated without evidence of carcinogenesis, nor
was this a consequence of the earlier radiotherapeutic treatment of this condition.
Since, however, such tumours might not arise until after a latency of perhaps
twenty years, we shall not know for certain for another ten years whether the
risk is negligible. If, then, the risk turns out to be over 1 per cent., the treatment
should rarely be used unless both surgery and thiouracil therapy are attended by
serious hazards to life; but if the risk of carcinogenesis is less than, say 0.1 per
cent., radioiodine may well offer the treatment of choice in Graves's disease, unless
by then we have achieved a less barbarous therapy than by mutilating the over-
stimulated gland. Meanwhile, I think that this treatment should be used whenever
both thiouracil and surgery are impossible or hazardous, and particularly in
patients over 45, in whom the expectation of life is in any case comparable with
the twenty years' latency of any possible carcinogenesis.
When we turn to the radioiodine treatment of thyroid carcinoma, of course,
this consideration of possible carcinogenesis loses its weight, and here I think
that radioiodine therapy is clinically obligatory in certain cases. We require to be
able to select those tumours of which the cells or follicles concentrate iodine, since
they will then concentrate radioiodine and may be destroyed by the intense local
radiation that will result. The clearest initial guide in the selection of patients
for this treatment appears to-lie in the histological pattern of the tumour (Fitzgerald
and Foote, 1949). For anaplastic thyroid carcinomata, radioiodine is unlikely to
be helpful, because such tumours do not usually appear to concentrate and retain
iodine, although some have been shown to do so. It is those tumours which are
histologically well differentiated, with colloid-filled alveoli resembling normal
thyroid tissue, which are also biochemically well differentiated and resemble normal
thyroid tissue in concentrating and retaining radioiodine, although rarely as
efficiently as does the normal gland. Unfortunately, this radioiodine concentration
in the tumour is rarely present or demonstrable while the normal thyroid is
functioning. Only after the removal or destruction of the thyroid gland does
the tumour take over this function and become accessible to treatment with radio-
iodine. The management of patients suspected of thyroid carcinoma would thus
appear to involve:
radical surgical resection if possible and if the diagnosis is confirmed. Otherwise
biopsy if practicable, with conventional radiotherapy for any suitable anaplastic
tumour. For differentiated tumours, removal of all normal thyroid tissue, either
surgically or by a first dose of radioiodine; then if radioiodine uptake can be
28demonstrated in the remaining tumour tissue, repeated large doses of radio-
iodine at one- to three-month intervals. WVe have had thirty-five patients
on such treatment ancd have observed obvious improvement in fourteen cases, and
eleven others continue symptom-free under treatment. It is not yet four years
since the start of treatment in any of these patients, so we cannot speak of a
curative effect upon what is in any case often a slowly growing type of tumour.
From the present results, however, radioiodine offers a treatment for differenti-
ated thvroi(d carcinomata which is often at least of very obvious palliative value
and mavxwell prove to be curative even though multiple bony or pulmonary
metastases have already occurred wxhen the patient is first treated.
I would not wish to conclude this account without giving some indication of
the tx'pe of hazard that the use of these methods, say of radioiodine for thyroid
carcinoma, involves. To the patient, the hazard is small if changes in the bJood
count are closely watched. Only a rather mild radiation sickness, a brief
lymphopenia, and occasional and transient swelling in the region of the tumour
hiave occturred in our experience of about a hundred 100 mC doses. The nursing
and laboratory staff, however, who may be dlealing with several hundred millicuries
a week, will require to observe certain rather strict precautions in their work if
their radiationi exposure is to be kept to the accepted low permissible figures
regal cled as safe for continuing exposure. WVe have found that a comnbination
of quite simple methods will prevent any undue exposure-involving nothing
more exacting than the methods of a bacteriologist handling pathogens, a surgeon
handling radium, andl sonme of the routine methods of barrier nursing. On this
basis the patient may, if necessary, be nursed in a general ward with normal bed
spacing and without restriction as to visitors, but nurses should use rubber gloves
for the care of such patients, or anv handling of their bedpans, in the first week
from the dose, an(l uirine may require to be kept for periods of up to eight weeks
before its radioactivity is low enough to permit its rejection. The laboratory
precautions require to be even more punctilious, since the (lose is received in a
solution of wxhich the accidental ing-estion should not on anv day exceed one twenty-
thousanditlh of a millilitre, and the day's permissible radiationi would be received
within one secoll(l by ain part of the bodv within half an inch of a 100 mC dose.
The opportunLities for therapy w%ith radlioiodinie are unusually favourable, since
the element may be highly concentrated in the tissue which requires treatment.
The control of polycvthemia by repeatedi (loses of radiophosphorus (Stroebel and
Hall, 1951) is due to a similar, although less great, local concentration of the
phosphorus not only in the rapidly dividing marrow cells, but also in the surround-
ing bone. And such types of treatment are ol general application. Wherever any
element, or chemical compound, or formecl structure can be found to enter the
diseased tissue in hligher concentration than in normnal tissues, we have the
opportunity of irr-adiating the diseased tissue selectively by giving the elernent
in radioactive form, or by incorporating a radioactive isotope stably into the
compound or the structure so concentrated. And it is obvious that methods of
29
Kthis type may increase in number and importance in the years to come. Here is
an open field for imaginative planning and detailed biochemistry, and the thera-
peutic applications of the radioactive isotopes offer as fertile a ground for
investigation as their diagnostic uses. Twenty years ago this chapter in medical
investigation had not opened. To-day I think we are still at the beginning of the
chapter.
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